Current strategies to deplete Tregs by using monoclonal antibodies to target cell surface proteins such as
CD25 and GITR have demonstrated mixed results, perhaps because
CD25 and GITR are also expressed in CD4 and CD8 effector T-cells, resulting in the mAbs killing both the Tregs and the effector T-cells.
We used the combination of the surface markers CD4,
CD25, and CD127 to identify Tregs.
Splenocytes were stained with anti-mouse CD4 mAb and anti-mouse
CD25 mAb (7D4) after incubation with the 2.4G2 antibody.
T cell proliferative response was assessed against bovine collagen II by measuring incorporation of bromodeoxyuridine into deoxyribonucleic acid of proliferating cells and by expression of
CD25 on proliferating cells as percentage of CD3+/bromodeoxyuridine+ and CD3+/CD25+ T-cells, respectively.
Decidual and peripheral blood CD4 +
CD25 + regulatory T cells in early pregnancy subjects and spontaneous abortion cases.
Her soluble
CD25 eventually returned and was elevated at 9420 pg/mL.
Though Tregs in mice express
CD25 constitutively, in humans only those with
CD25 show suppressive function.10 Leprosy reactions in contrast showed a decrease in Treg cells which paralleled the increase in Th17 population.11 Moreover, there was downregulation of intracellular TGF-[beta].11,12 Most reports showed a reduction in Treg cells in patients with ENL reactions compared with non-reaction lepromatous leprosy counterparts.11,12
Regulatory T cells come in many forms with the most well-understood being those that express the markers CD4,
CD25, and FOXP3.
Tusk Therapeutics, Cancer Research UK (via its Commercial Partnerships Team) and UCL announced in 2017, an exclusive licensing and collaboration deal to develop and commercialise antibody-based therapeutics against
CD25.
Although different T cell types with regulatory functions have been identified, the most physiologically relevant Treg population is characterized as [CD4.sup.+] T lymphocytes that constitutively express the IL-2 receptor a-chain,
CD25, and the transcription factor Foxp3, comprising approximately 10% of the [CD4.sup.+] T cell compartment [5].